Carmot Therapeutics is a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes. The company is focused on developing a broad, wholly-owned pipeline of novel incretin agonists using their Chemotype Evolution platform, with the potential to produce significant weight loss and glycemic control. Carmot Therapeutics has three clinical-stage product candidates and is committed to improving clinical outcomes for people living with metabolic diseases.

Carmot Therapeutics

The Column Group (TCG) is a science-driven venture capital firm that makes significant financial and operational commitments to build early stage drug discovery companies based on their unique scientific platforms and potential to deliver multiple breakthrough therapeutics.

TCG’s investment strategy runs counter to the prevailing trend in life sciences venture capital toward assembling diversified portfolios of later stage, single product-orientated companies across multiple industry sectors, with proximity to value inflection points and the early identification of a Pharma “buyer” as key investment considerations.

In contrast, TCG takes the long view in making investments, recognizing that significant time is often required to generate significant value. Our approach is not “building-to-exit.” Key variables, including scientific opportunities, the competitive and regulatory landscape, and Pharma priorities, can change very rapidly. Instead, TCG’s mission is the generation of fundamentally strong companies, built from the ground up based on great science and the ability to generate multiple differentiated product opportunities.

Rather than diversification, TCG emphasizes focus. We are dedicated to early stage drug discovery as the best source of a new generation of novel, highly effective human therapies. We believe that the most critical resources, such as great ideas, world class founders, and top quality managerial and scientific talent, are very rare and that concentrating them within a small cohort of companies is the key path to success.

TCG is about the bold pursuit of big ideas using innovative science to generate breakthrough therapies that address significant diseases. Our firm is committed to all facets of company building and brings together a rich combination of scientific, financial and operational expertise to shape promising science into a value-rich portfolio poised to have a profound impact on human health.

Surrozen

Tenaya Therapeutics

Arcus Biosciences

Gritstone bio

Revolution Medicines

Constellation Pharmaceuticals

Effector Therapeutics

Flexus Biosciences

NGM Biopharmaceuticals

Nurix Therapeutics

ORIC Pharmaceuticals

Rapt Therapeutics

Peloton Therapeutics

PTC Therapeutics

The Column Group

See all job openings posted by The Column Group's portfolio companies on our Careers page!

https://lnkd.in/gtyHpGbq

Revolution Medicines Announces Commencement of Public Offering of Common Stock

https://lnkd.in/dXkda_Tg

NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results

https://lnkd.in/dAN3rx_q

Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress

https://lnkd.in/dymRFhNw

eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID

https://lnkd.in/dgsXggex

Neurona Therapeutics Announces FDA Clearance of Expanded Inclusion Criteria for Phase I/II Clinical Trial of NRTX-1001 Regenerative Cell Therapy in Patients with Dominant Hemisphere Drug-Resistant Focal Epilepsy

https://lnkd.in/dKya-gpx

Hexagon Bio Raises $77.3 Million Series B Financing and Strengthens Leadership to Expand Novel Computational Discovery Platform and Advance Microbial Genome-Derived Small Molecules

https://lnkd.in/edigtAQb

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update

https://lnkd.in/dpsvj86y

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

https://lnkd.in/dVUMEtAV

Casma Therapeutics Announces CEO Transition

https://lnkd.in/emawtHVj

US:CARMOT

Carmot Therapeutics